Completion of CAP accreditation audit

Verici Dx

12/11/2025 07:00

RNS Number : 1171H

Verici Dx PLC

12 November 2025

 

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Completion of CAP accreditation audit

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists ("CAP"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.

 

The inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.

 

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now. We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians."

 

Verici Dx plc
www.vericidx.com
Sara Barrington, CEO
Via Walbrook PR
Singer Capital Markets (Nominated adviser, Joint Broker)
Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Paul McManus
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893


 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRABBBATMTTBBLA